成纤维细胞生长因子受体2融合蛋白作为治疗胆管癌的靶点
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
作者信息
Borad Mitesh J, Gores Gregory J, Roberts Lewis R
机构信息
aDivision of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona bDepartment of Molecular Medicine cDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Curr Opin Gastroenterol. 2015 May;31(3):264-8. doi: 10.1097/MOG.0000000000000171.
Abstract
PURPOSE OF REVIEW
This review will cover the role of the fibroblast growth factor pathway in the pathogenesis, targeted therapy potential and prognostic value in patients with cholangiocarcinoma (CCA).
RECENT FINDINGS
Recent studies that have identified fibroblast growth factor receptor 2 (FGFR2) fusions, prognostic implications of FGFR2 fusions, treatment strategies that target FGFR2 in CCA and future directions for understanding and targeting the FGFR2 pathway in this disease, will be discussed.
SUMMARY
Understanding the role of the FGFR2 pathway as a disease pathogenetic mechanism and the ability to develop targeted therapies and diagnostics surrounding this concept are critical elements toward developing novel targeted approaches in CCA.
摘要
综述目的
本综述将涵盖成纤维细胞生长因子通路在胆管癌（CCA）患者发病机制、靶向治疗潜力及预后价值中的作用。
最新发现
将讨论近期已鉴定出成纤维细胞生长因子受体2（FGFR2）融合、FGFR2融合的预后意义、CCA中靶向FGFR2的治疗策略以及理解和靶向该疾病中FGFR2通路的未来方向。
总结
了解FGFR2通路作为疾病致病机制的作用以及围绕这一概念开发靶向治疗和诊断方法的能力，是在CCA中开发新型靶向方法的关键要素。
相似文献
1
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.成纤维细胞生长因子受体2融合蛋白作为治疗胆管癌的靶点
Curr Opin Gastroenterol. 2015 May;31(3):264-8. doi: 10.1097/MOG.0000000000000171.
2
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.肝内胆管癌中的成纤维细胞生长因子受体 2 易位。
Hum Pathol. 2014 Aug;45(8):1630-8. doi: 10.1016/j.humpath.2014.03.014. Epub 2014 Apr 13.
3
Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.FGFR2 易位的类型决定了肝内胆管癌靶向治疗的反应。
Cell Death Dis. 2021 Mar 11;12(3):256. doi: 10.1038/s41419-021-03548-4.
4
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.综合基因组特征揭示了散发性肝内胆管癌中FGFR和EGFR通路中新型的、具有治疗相关性的药物靶点。
PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb.
5
testing in cholangiocarcinoma: translating molecular studies into clinical practice.在胆管癌中的检测：将分子研究转化为临床实践。
Pathologica. 2023 Apr;115(2):71-82. doi: 10.32074/1591-951X-859. Epub 2023 Apr 5.
6
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.胆管癌靶向治疗的现状与新兴靶点
Oncotarget. 2016 Jul 19;7(29):46750-46767. doi: 10.18632/oncotarget.8775.
7
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.趋同的丝裂原活化蛋白激酶（MAPK）信号通路改变介导FGFR2融合阳性胆管癌对FGFR抑制剂的获得性耐药。
J Hepatol. 2024 Feb;80(2):322-334. doi: 10.1016/j.jhep.2023.10.041. Epub 2023 Nov 14.
8
Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.成纤维细胞生长因子受体 2（FGFR2）融合在日本肝内胆管癌患者中的研究。
Jpn J Clin Oncol. 2021 May 28;51(6):911-917. doi: 10.1093/jjco/hyab029.
9
Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond.靶向成纤维细胞生长因子受体通路：胆管癌的精准医学及其他。
Semin Liver Dis. 2023 May;43(2):218-225. doi: 10.1055/a-2049-3149. Epub 2023 Mar 7.
10
Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.针对胆管癌中 FGFR2 融合的联合疗法。
Trends Cancer. 2022 Feb;8(2):83-86. doi: 10.1016/j.trecan.2021.11.001. Epub 2021 Nov 25.
引用本文的文献
1
Identification of potent biparatopic antibodies targeting FGFR2 fusion-driven cholangiocarcinoma.靶向FGFR2融合驱动的胆管癌的强效双特异性抗体的鉴定。
J Clin Invest. 2025 Feb 27;135(8). doi: 10.1172/JCI182417. eCollection 2025 Apr 15.
2
Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.tasurgratinib用于胆管癌或胃癌患者：首例人体I期研究的扩展部分
Cancer Sci. 2025 Jan;116(1):192-203. doi: 10.1111/cas.16354. Epub 2024 Oct 27.
3
A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma.一种连接天冬酰胺耗竭的DNA/RNA异源双链寡核苷酸可抑制FGFR2融合驱动的肝内胆管癌。
Mol Ther Nucleic Acids. 2023 Oct 5;34:102047. doi: 10.1016/j.omtn.2023.102047. eCollection 2023 Dec 12.
4
Molecular Detection of Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype.肝内胆管癌切除标本中重排的分子检测：荧光原位杂交技术可能是组织学小胆管亚型患者的理想检测方法。
J Clin Transl Hepatol. 2023 Nov 28;11(6):1355-1367. doi: 10.14218/JCTH.2022.00060S. Epub 2023 Jul 27.
5
A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients.一种用于检测肝内胆管癌患者FGFR2易位的稳健荧光原位杂交检测方法。
Diagnostics (Basel). 2023 Jun 16;13(12):2088. doi: 10.3390/diagnostics13122088.
6
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.在日本晚期实体瘤患者中进行不可逆成纤维细胞生长因子受体 1-4 抑制剂 futibatinib 的 I 期研究。
Cancer Sci. 2023 Feb;114(2):574-585. doi: 10.1111/cas.15486. Epub 2022 Dec 4.
7
Prognostic and Predictive Molecular Markers in Cholangiocarcinoma.胆管癌的预后和预测分子标志物
Cancers (Basel). 2022 Feb 17;14(4):1026. doi: 10.3390/cancers14041026.
8
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience.成纤维细胞生长因子受体抑制剂在胆管癌中的毒性和疗效：多中心单机构队列经验。
JCO Precis Oncol. 2021 Jul 28;5. doi: 10.1200/PO.21.00064. eCollection 2021.
9
Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.中国乳腺癌中受体酪氨酸激酶融合基因的分析
Front Oncol. 2021 Sep 28;11:741142. doi: 10.3389/fonc.2021.741142. eCollection 2021.
10
Whole Exome Sequencing of Biliary Tubulopapillary Neoplasms Reveals Common Mutations in Chromatin Remodeling Genes.胆管微乳头状肿瘤的全外显子组测序揭示了染色质重塑基因中的常见突变。
Cancers (Basel). 2021 Jun 1;13(11):2742. doi: 10.3390/cancers13112742.
本文引用的文献
1
Anchored multiplex PCR for targeted next-generation sequencing.靶向下一代测序的锚定多重 PCR。
Nat Med. 2014 Dec;20(12):1479-84. doi: 10.1038/nm.3729. Epub 2014 Nov 10.
2
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.肝内胆管癌中的成纤维细胞生长因子受体 2 易位。
Hum Pathol. 2014 Aug;45(8):1630-8. doi: 10.1016/j.humpath.2014.03.014. Epub 2014 Apr 13.
3
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.膀胱癌中的FGFR3易位：基于药物代谢对HSP90抑制的差异敏感性
Mol Cancer Res. 2014 Jul;12(7):1042-54. doi: 10.1158/1541-7786.MCR-14-0004. Epub 2014 Apr 30.
4
Cholangiocarcinoma.胆管癌。
Lancet. 2014 Jun 21;383(9935):2168-79. doi: 10.1016/S0140-6736(13)61903-0. Epub 2014 Feb 26.
5
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.二代测序揭示肝内胆管癌靶向治疗的新途径
Oncologist. 2014 Mar;19(3):235-42. doi: 10.1634/theoncologist.2013-0352. Epub 2014 Feb 21.
6
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.综合基因组特征揭示了散发性肝内胆管癌中FGFR和EGFR通路中新型的、具有治疗相关性的药物靶点。
PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb.
7
Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.PTPN3 中的激活突变促进胆管癌细胞增殖和迁移，并与患者肿瘤复发相关。
Gastroenterology. 2014 May;146(5):1397-407. doi: 10.1053/j.gastro.2014.01.062. Epub 2014 Feb 4.
8
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.外显子组测序鉴定出肝吸虫相关和非感染相关胆管癌中的不同突变模式。
Nat Genet. 2013 Dec;45(12):1474-8. doi: 10.1038/ng.2806. Epub 2013 Nov 3.
9
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.外显子组测序鉴定出肝内胆管癌中 BAP1、ARID1A 和 PBRM1 的频发失活突变。
Nat Genet. 2013 Dec;45(12):1470-1473. doi: 10.1038/ng.2813. Epub 2013 Nov 3.
10
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.成纤维细胞生长因子受体 2 酪氨酸激酶融合定义了胆管癌的一个独特分子亚型。
Hepatology. 2014 Apr;59(4):1427-34. doi: 10.1002/hep.26890. Epub 2014 Feb 18.
Zotero 插件